Hanlikang, commonly known as rituximab injection, is mainly used in the treatment of non-Hodgkin’s lymphoma (NHL).
Rituximab Injection (Hanlikang) is developed by Shanghai Fuhong Hanlin Biopharmaceutical Co., Ltd. and is a product developed and declared for production according to the biosimilar pathway using Genentech’s original rituximab as the reference drug, and has been supported by the National Major Project for Scientific and Technological Creation of New Drugs, the first biosimilar formulation in China.
It is mainly indicated for the treatment of three subclasses of NHL, including relapsed or drug-resistant follicular central lymphoma, previously untreated CD20-positive stage III-IV follicular non-Hodgkin lymphoma, and CD20 diffuse large B-cell non-Hodgkin lymphoma.
It is worth noting that, for the same disease, patients have different physical conditions and different stages of disease development, so their treatment methods are also different. Therefore, it is recommended that patients go to regular hospitals to find a specialist for consultation, and standardize the use of medication under the guidance of the doctor, and do not take medication without authorization.